On February 16, 2023 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that it will report fourth quarter and full year 2022 financial results after U.S. financial markets close on Thursday, February 23, 2023 (Press release, Kura Oncology, FEB 16, 2023, View Source [SID1234627306]). Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the teleconference, domestic callers should dial 1-877-407-4018 and international callers should dial 1-201-689-8471. A live webcast of the call can be accessed using this weblink: View Source;tp_key=5fdc524c8f. A replay of the webcast will be available online from the investor relations section of the company website at www.kuraoncology.com.

On February 16, 2023 ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, reported Dr. Karim Chamie, Associate Professor of Urology at UCLA, will be presenting "Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG" at the ASCO (Free ASCO Whitepaper) Genitourinary Cancers Symposium (ASCO GU) conference in San Francisco, February 16-18 (Press release, ImmunityBio, FEB 16, 2023, View Source [SID1234627305]). The Food and Drug Administration (FDA) is currently reviewing the Biologics License Application (BLA) for ImmunityBio’s N-803 plus BCG for the treatment of NMIBC CIS with a Prescription Drug User Fee Act (PDUFA) date of May 23, 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details about the presentation are below:

Date: February 16, 2023
Track: Urothelial Carcinoma, Prostate Cancer-Advanced
Sub-Track: Symptoms, Toxicities, Patient-Reported Outcomes and Whole-Person Care
Title: Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG
Presenter: Dr. Karim Chamie, Associate Professor of Urology at UCLA
Session: Poster Session B: Prostate Cancer and Urothelial Carcinoma
Abstract #: 495
Location: Poster Board J17
Session Times: 11:30 a.m.-1:00 p.m.; 5:45-6:45 p.m. PST

Participants are also invited to attend ImmunityBio’s Medical Affairs booth (#65). For full session details and scientific presentation listings, please see the ASCO (Free ASCO Whitepaper) GU online program.

On February 16, 2023 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, reported its fourth quarter and full-year 2022 financial results and operational highlights in a conference call on February 23, 2023, at 8 a.m. ET (Press release, Intellia, FEB 16, 2023, View Source [SID1234627303]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To join the call:

U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.
Please visit this link for a simultaneous live webcast of the call.
A replay of the call will be available through the Events and Presentations page of the Investors & Media section on Intellia’s website at www.intelliatx.com, beginning on February 23, 2023, at 12 p.m. ET.

On February 16, 2023 GlycoMimetics, Inc. (the "Company") (NASDAQ:GLYC) reported that the Compensation Committee of the Company’s Board of Directors approved the grant on February 10, 2023 of a non-qualified stock option award to purchase an aggregate of 150,000 shares to Chinmaya Rath, the Company’s new Senior Vice President and Chief Business Officer (Press release, GlycoMimetics, FEB 16, 2023, View Source [SID1234627300]). The award was granted as an inducement equity award outside of the Company’s Amended and Restated 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4) and was made as an inducement material to the acceptance of employment with the Company by the new employee.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The award was comprised of an option to purchase 150,000 shares of the Company’s common stock, par value $0.001 per share (the "Common Stock"), subject to vesting as to 25% of the underlying shares on February 10, 2024, and as to the remaining underlying shares in equal monthly installments over 36 months thereafter. The option grant has an exercise price of $3.48 per share, the closing price of the Common Stock on the date of grant, and is subject to the terms and conditions of a stock option agreement and the GlycoMimetics, Inc. Inducement Plan (adopted January 22, 2020 and amended on August 2, 2021 and January 21, 2022), which provides for the granting of stock options and other equity awards to new employees.

On February 16, 2023 Geron Corporation (Nasdaq: GERN) reported that it has granted non-statutory stock options to purchase an aggregate of 640,550 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company (Press release, Geron, FEB 16, 2023, View Source [SID1234627299]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The stock options were granted on February 15, 2023 at an exercise price of $2.69 per share, which is equal to the closing price of Geron common stock on the date of grant. Stock options representing an aggregate of 595,800 shares have a 10-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment for the respective employees and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates. Stock options representing an aggregate of 44,750 shares have a 10-year term and vest in full upon achievement of certain regulatory milestones, subject to continued employment with Geron through the applicable vesting dates. All of the stock options were granted as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the stock option agreements covering the grants and Geron’s 2018 Inducement Award Plan, which was adopted December 14, 2018 and provides for the granting of stock options to new employees.